{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T14:52:25Z","timestamp":1781621545421,"version":"3.54.5"},"reference-count":36,"publisher":"Centre for Evaluation in Education and Science (CEON\/CEES)","issue":"6","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/BY\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Med Biochemistry"],"published-print":{"date-parts":[[2026]]},"abstract":"<jats:p>Background: To investigate the clinical use of Sclerostin, tartrate-resistant acid phosphatase 5b (TRACP-5b), and serum C-C motif chemokine ligand 3 (CCL3) levels in assessing the health and prognosis of patients with multiple myeloma. Methods: A total of 250 patients with multiple myeloma who visited the hospital between January 2023 and December 2024 were included as the observation group, while 150 healthy individuals evaluated during the same period served as the control group. Serum levels of CCL3, TRACP-5b, and Sclerostin were measured and compared in the observation group before and after treatment. Additionally, serum levels of these markers were analysed in MM patients with different tumour stages and varying degrees of bone destruction. Univariate and multivariate analyses were performed to identify factors associated with death within one year in MM patients. Finally, the predictive efficacy of single and combined detection of serum CCL3, TRACP-5b, and Sclerostin for one-year mortality in multiple myeloma patients was evaluated. Results: The levels of serum CCL3, TRACP-5b, and Sclerostin in the observation group before and after treatment were significantly greater than those in the control group, and the differences were statistically significant (P&amp;lt;0.05). After treatment, the levels of serum CCL3, TRACP-5b, and Sclerostin in the observation group were significantly lower than those before treatment, and the differences were statistically significant (P&amp;lt; 0.05). There were statistically significant differences in tumour stage, classification of bone destruction, CCL3 level, TRACP-5b level, and Sclerostin level (P&amp;lt;0.05). Multivariate analysis revealed that tumour stage, the degree of bone destruction, the CCL3 level, the TRACP-5b level, and the Sclerostin level were factors influencing death within 1 year in patients with multiple myeloma (P&amp;lt;0.05). The levels of serum CCL3, TRACP-5b, and Sclerostin have relatively high predictive value for death within 1 year in patients with multiple myeloma. The sensitivity of the combined detection of the three indicators was 90.3%, the specificity was 87.4%, and the area under the receiver operating characteristic curve (AUC) was 0.937, which was significantly greater than that of CCL3 (Z = 3 .0 6 1 , P=0.002), TRACP-5b (Z= 3.625, P&amp;lt;0.001), and Sclerostin (Z= 2.579). When tested separately (P= 0.010), there was no statistically significant difference in AUC among the three indicators (P&amp;gt;0.05). Conclusions: CCL3, TRACP-5b, and Sclerostin are involved in the development and progression of multiple myeloma and have high predictive value for death within 1 year.<\/jats:p>","DOI":"10.5937\/jomb0-62533","type":"journal-article","created":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T09:08:12Z","timestamp":1766394492000},"page":"1286-1294","source":"Crossref","is-referenced-by-count":0,"title":["Correlation analysis of serum CCL3, TRACP-5b, and sclerostin with the prognosis of multiple myeloma patients"],"prefix":"10.5937","volume":"45","author":[{"given":"Cuimei","family":"Jiang","sequence":"first","affiliation":[{"name":"Tangshan People's Hospital, Department of Orthopaedics, Tangshan City, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manman","family":"Sun","sequence":"additional","affiliation":[{"name":"Huai'an Hospital of Huai'an City (Huai'an Clinical Medical College of Jiangsu University), Department of Hospital Infection, Huai'an District, Huai'an City, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dashan","family":"Gao","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital of Zhengzhou University, Department of Oncology, Erqi District, Zhengzhou City, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoli","family":"Zhang","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital of Zhengzhou University, Department of Oncology, Erqi District, Zhengzhou City, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianan","family":"Pan","sequence":"additional","affiliation":[{"name":"The First People's Hospital of Taizhou, Department of Orthopaedics, Zhejiang Province, Affiliated to Wenzhou Medical University, Taizhou City, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3964","reference":[{"key":"ref1","doi-asserted-by":"crossref","unstructured":"Maura F , Rajanna AR, Ziccheddu B, Poos AM, Derkach A, Maclachlan K, Durante M, Diamond B, Papadimitriou M, Davies F Boyle EM, Walker B, Hultcrantz M, Silva A, Hampton O, Teer JK, Siegel EM, Bolli N, Jackson GH, Kaiser M, Pawlyn C, Cook G, Kazandjian D, Stein C, Chesi M, Bergsagel L, Mai EK, Goldschmidt H, Weisel KC, Fenk R, Raab MS, Van Rhee F Usmani S, Shain KH, Weinhold N, Morgan G, Landgren O. Genomic Classification and Individualized Prognosis in Multiple Myeloma. J Clin Oncol 2024 Apr 10; 42(11): 1229-40. doi: 10.1200\/JCO .23.01277. Epub 2024 Jan 9. PMID: 38194610; PMCID: PMC11095887;","DOI":"10.1200\/JCO.23.01277"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Tavakoli Pirzaman A, Ebrahimi P Hasanpour AH, Shakeri M, Babajani B, Pourali Ganji Z, Babaei H, Rahmati A, Hosseinzadeh R, Doostmohamadian S, Kazemi S. miRNAs and Multiple Myeloma: Focus on the Patho-genesis, Prognosis, and Drug Resistance. Technol Cancer Res Treat 2023 Jan-Dec; 22: 15330338231202391. doi: 10.1177\/15330338231202391. PMID: 37728167; PMCID: PMC10515583;","DOI":"10.1177\/15330338231202391"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Sun C, Zhang W, Liu H, Ding Y, Guo J, Xiong S, Zhai Z, Hu W. Identification of a novel lactylation-related gene signature predicts the prognosis of multiple myeloma and experiment verification. Sci Rep 2024 Jul 2; 14(1): 15142. doi: 10.1038\/s41598-024-65937-x. PMID: 38956267; PMCID: PMC11219856;","DOI":"10.1038\/s41598-024-65937-x"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Thakral B, Vijayanarayanan A, Medeiros LJ, Lin P Cytogenetic and molecular aberrations at diagnosis and in prognosis of multiple myeloma. Semin Diagn Pathol 2025 Jul; 42(4): 150915. doi: 10.1016\/j.semdp. 2025.150915. Epub 2025 May 17. PMID: 40411938;","DOI":"10.1016\/j.semdp.2025.150915"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"Seegmiller AC. Flow cytometry in the diagnosis and prognosis of multiple myeloma. Semin Diagn Pathol 2025 Sep; 42(5): 150942. doi: 10.1016\/j.semdp. 2025.150942. Epub 2025 Jul 25. PMID: 40743872;","DOI":"10.1016\/j.semdp.2025.150942"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"Martello M, Solli V, Mazzocchetti G, Solimando AG, Bezzi D, Taurisano B, Kanapari A, Poletti A, Borsi E, Armuzzi S, Vigliotta I, Pistis I, Desantis V, Marzocchi G, Rizzello I, Pantani L, Mancuso K, Tacchetti P Testoni N, Nanni C, Zamagni E, Cavo M, Terragna C. High level of circulating cell-free tumor DNA at diagnosis correlates with disease spreading and defines multiple myeloma patients with poor prognosis. Blood Cancer J 2024 Nov 28; 14(1): 208. doi: 1 0 .1 038\/s41408-024-01185-6. PMID: 39609411; PMCID: PMC11605000;","DOI":"10.1038\/s41408-024-01185-6"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Martinez-Cordero H, Pena C, Schutz NP Bove V, Villano F, Beltran C, Donoso J, Lopez-Vidal H, Roa Salinas MA, Soto P , Ochoa P , Duarte P , Remaggi G, Corzo A, Shanley C, Lopresti S, Orlando S, Verri V, Quiroga LD, Fantl D, Ramirez J, Ospina-Idarraga A, Idrobo H, Quintero G, Gomez R, Cantu-Martinez O, Gomez-Almaguer D, Ruiz-Arguelles GJ, Galvez-Cardenas KM, Salazar LA, Novoa-Caicedo I, Fuentes-Lacouture MC, Spirko P Arbelaez MI, Pereira M, Valdes J, Vasquez J, von Glasenapp A, Riva E; GELAM M (Grupo de Estudio Latinoamericano de Mieloma Multiple). Patients Age 40 Years and Younger With Multiple Myeloma Have the Same Prognosis as Older Patients: An Analysis of Real-World Patients' Evidence From Latin America. JCO Glob Oncol 2023 Sep; 9: e2300182. doi: 10.1200\/GO .23.00182. PMID: 38060975; PMCID: PMC10723854;","DOI":"10.1200\/GO.23.00182"},{"key":"ref8","unstructured":"Liang D, Li X , Bai S, Wang Q, Zeng M, Feng D, Lu B, Li X , Sun Z, Li J, Zhou H, Zhang J, Chen X , Xia Z, Liang Y, Wang H. Clinical Outcome of Induction Treatment in the Era of Novel Agents and the Impact of the Number of High-Risk Cytogenetic Abnormalities (HRA) on Prognosis of Patients With Newly Diagnosed Multiple Myeloma (NDMM): Insights From a Multicenter Study. Cancer Med 2024 Oct; 13(20): e70270. doi: 10.1002\/ cam 4.70270. Erratum in: Cancer Med. 2024 Nov; 13(21): e70406. doi: 10.1002\/cam 4.70406. PMID: 39422477; PMCID: PMC11487677;"},{"key":"ref9","unstructured":"Shen N, Zhang J, Xia Y, Shen X X , Wang J, Jin YY, Zhang R, Li JY Chen LJ. Clinical characteristics and prognosis of newly diagnosed multiple myeloma patients with FGFR3 gene mutations. Zhonghua Xue Y Xue Za Zhi 2023 Dec 14; 44(12): 989-94. Chinese. doi: 10.3760\/ cm a.j.issn.0253-2727.2023.12.004. PMID: 38503521; PMCID: PMC10834875;"},{"key":"#cr-split#-ref10.1","doi-asserted-by":"crossref","unstructured":"Yu K, Li J, Chen D, Huan W. The Correlation of miR-671-5p with Diagnosis and Prognosis in Multiple Myeloma. Clin Lab 2023 Aug 1","DOI":"10.7754\/Clin.Lab.2023.220826"},{"key":"#cr-split#-ref10.2","unstructured":"69(8). doi: 10.7754\/Clin.Lab. 2023.220826. PMID: 37560870;"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Solmaz S, Uzun O, Sevindik OG, Demirkan F Ozcan MA, Ozsan GH, Alacacioglu I. The effect of hemoglobin, albumin, lymphocyte and platelet score on the prognosis in patients with multiple myeloma. Int J Lab Hematol 2023 Feb; 45(1): 13-9. doi: 10.1111\/ijlh.13958. Epub 2022 Sep 2. PMID: 36053932;","DOI":"10.1111\/ijlh.13958"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"Wu L, Zheng Y Liu J, Luo R, Wu D, Xu P Wu D, Li X. Comprehensive evaluation of the efficacy and safety of LPV\/r drugs in the treatment of SARS and MERS to pro-vide potential treatment options for COVID-19. Aging (Albany NY) 2021 Apr 20; 13(8): 10833-52. doi: 10.18632\/aging.202860. Epub 2021 Apr 20. PMID: 33879634; PMCID: PMC8109137;","DOI":"10.18632\/aging.202860"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"Chen H, Zhao Y Zhang Z, Xie Y Jin M. Immuno-pheno-typic characteristics and prognostic value of peripheral blood circulating plasma cells in patients with newly diag-nosed multiple myeloma. J Med Biochem 2025; 44 (3): 668-77;","DOI":"10.5937\/jomb0-55319"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"Tang S, Long X, Li F Jiang S, Fu Y, Liu J. Identification of RUVBL2 as a novel biomarker to predict the prognosis and drug sensitivity in multiple myeloma based on ferrop-to-sis genes. Hematology 2025 Dec; 30(1): 2467499. doi: 10.1080\/16078454.2025.2467499. Epub 2025 Feb 21. PMID: 39985176;","DOI":"10.1080\/16078454.2025.2467499"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"Li JR, Parthasarathy AK, Kannappan AS, Arsang-Jang S, Dong J, Cheng C. Characterization of driver muta-tions identifies gene signatures predictive of prognosis and treatment sensitivity in multiple myeloma. Oncologist 2024 Nov 4; 29(11): e1552-e1564. doi: 10.1093\/oncolo\/oyae244. PMID: 39250742; PMCID: PM C11639189;","DOI":"10.1093\/oncolo\/oyae244"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"Wu L, Zhong Y, Wu D, Xu P Ruan X , Yan J, Liu J, Li X. Immunomodulatory Factor TIM3 of Cytolytic Active Genes Affected the Survival and Prognosis of Lung Adenocarcinoma Patients by Multi-Omics Analysis. Biomedicines 2022 Sep 10; 10(9): 2248. doi: 10.3390\/ biomedicines10092248. PMID: 36140350; PMCID: PMC9496572;","DOI":"10.3390\/biomedicines10092248"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"Bao L, Wang YT, Lu MQ, Chu B, Shi L, Gao S, Fang LJ, Xiang QQ, Ding YH , Liu X, Zhao X , Wang MZ, Chen Y, Hu WK. Vitamin D deficiency linked to abnormal bone and lipid metabolism predicts high-risk multiple myeloma with poorer prognosis. Front Endocrinol (Lausanne) 2023 Apr 27; 14: 1157969. doi: 10.3389\/fendo.2023. 1157969. PMID: 37181039; PMCID: PMC10173308;","DOI":"10.3389\/fendo.2023.1157969"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"Zhong H, Huang D, Wu J, Chen X , Chen Y Huang C. 18F FDG PET\/CT based radiomics features improve pre-diction of prognosis: multiple machine learning algo-rithms and multimodality applications for multiple myelo-ma. BMC Med Imaging 2023 Jun 27; 23(1): 87. doi: 10 .1186\/s12880-023-01033-2. PMID: 37370013; PMCID: PMC10303834;","DOI":"10.1186\/s12880-023-01033-2"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"Wu L, Liu Q, Ruan X , Luan X , Zhong Y Liu J, Yan J, Li X. Multiple Omics Analysis of the Role of RBM10 Gene Instability in Immune Regulation and Drug Sensitivity in Patients with Lung Adenocarcinoma (LUAD). Biome-dicines 2023 Jun 29; 11(7): 1861. doi: 10.3390\/bio-medicines11071861. PMID: 37509501; PMCID: PMC10377220;","DOI":"10.3390\/biomedicines11071861"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"Zhang Y, Pan J, Kang H, Peng S, Tung TH, Shen B. Prognosis of concurrent renal impairment at diagnosis of multiple myeloma: a systematic review. Ann Med 2024 Dec; 56(1): 2380301. doi: 10.1080\/07853890. 2024.2380301. Epub 2024 Jul 22. PMID: 39034813; PMCID: PMC11265304;","DOI":"10.1080\/07853890.2024.2380301"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"Jiang JY, Yao FY Liu J, Wang XL, Huang B, Zhong FM, Wang XZ . A Novel Necroptosis-Related Signature Can Predict Prognosis and Chemotherapy Sensitivity in Multiple Myeloma. Technol Cancer Res Treat 2024 Jan-Dec; 23: 15330338241232554. doi: 10.11 77\/ 15330338241232554. PMID: 38361483; PMCID: PMC10874153;","DOI":"10.1177\/15330338241232554"},{"key":"ref22","unstructured":"Wang JH, Xiang P Zhao EJ, Liu LN, Liu YZ , Liang LJ, Cui YS, Fang BJ. Impact of type 2 and steroid-Induced dia-betes mellitus on prognosis in patients with multiple myeloma. World J Surg Oncol 2025 Aug 30; 23(1): 330. doi: 1 0 .1 1 86\/s12957-025-03982-0. PMID: 40886007; PMCID: PMC12398977;"},{"key":"ref23","unstructured":"Zhang YQ , Zhao JS, Wei XF, Feng YF, Fu Y, Chen QL, Zhang QK. Clinical Characteristics and Prognosis of Patients with IgD Multiple Myeloma. Zhongguo Shi Yan Xue Ya Xue Za Zhi 2025 Apr; 33(2): 43 7-41. Chinese. doi: 10.1 9746\/j.cnki.issn.1009-2137.2025.02.018. PMID: 40326115;"},{"key":"ref24","unstructured":"Wu L, Zheng Y Ruan X , Wu D, Xu P Liu J, Wu D, Li X. Long-chain noncoding ribonucleic acids affect the sur-vival and prognosis of patients with esophageal adeno-carcinoma through the autophagy pathway: construc-tion of a prognostic model. Anticancer Drugs 2022 Jan 1; 3 3 (1): e590-e60 3. doi: 10 .1097\/C A D .00 00000000001189. PMID: 34338240; PMCID: PM C8670349;"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"O uzman H, Ka\u00e7maz M. The role of pentraxin 3 and oxidative status in the prognosis of multiple myeloma. J Investig Med 2024 Apr; 72(4): 333-40. doi: 10.1177\/ 10815589241235662. Epub 2024 Mar 13. PMID: 38373952;","DOI":"10.1177\/10815589241235662"},{"key":"ref26","doi-asserted-by":"crossref","unstructured":"Qiao X , Song Z, Geng L, Xing L, Wang Y. Investigating the role of tumor cell heterogeneity and angiogenesis genes in the prognosis of multiple myeloma. Front Immunol 2025 Jun 25; 16: 1610833. doi: 10.3389\/ fimmu.2025.1610833. PMID: 40636123; PMCID: PMC12238041;","DOI":"10.3389\/fimmu.2025.1610833"},{"key":"#cr-split#-ref27.1","doi-asserted-by":"crossref","unstructured":"Ji J, Guo R, Ma J, Cui Y, Li Y, Sun Z, Li J, Fan L, Qu X. Liquid extramedullary disease in multiple myeloma strongly predicts a poor prognosis and is associated with bortezomib resistance gene upregulation. Clin Chim Acta 2023 Aug 1","DOI":"10.1016\/j.cca.2023.117497"},{"key":"#cr-split#-ref27.2","unstructured":"548: 117497. doi: 10.1016\/j.cca.2023. 117497. Epub 2023 Jul 20. PMID: 37479009;"},{"key":"ref28","doi-asserted-by":"crossref","unstructured":"Yan H, Ding Y Dai W, Wang H, Qin H, Zhai Z, Tao Q. Identification and construction of a novel NET-related gene signature for predicting prognosis in multiple myeloma. Clin Exp Med 2025 May 9; 25(1): 147. doi: 10.1007\/s10238-025-01 692-1. PMID: 40346405; PMCID: PMC12064474;","DOI":"10.1007\/s10238-025-01692-1"},{"key":"ref29","doi-asserted-by":"crossref","unstructured":"Wu L, Zhong Y, Yu X , Wu D, Xu P Lv L, Ruan X , Liu Q, Feng Y, Liu J, Li X. Selective poly adenylation predicts the efficacy of immunotherapy in patients with lung adeno-carcinoma by multiple omics research. Anticancer Drugs 2022 Oct 1; 33(9): 943-59. doi: 10.1097\/CAD. 00 00000000001319. Epub 2022 Aug 9. PMID: 35946526; PMCID: PMC9481295;","DOI":"10.1097\/CAD.0000000000001319"},{"key":"ref30","doi-asserted-by":"crossref","unstructured":"Lei A, Liao X , Zhu P Xiong M. The significance of autol-ogous hematopoietic stem cell transplantation on immunoglobulin reconstitution and prognosis in elderly patients with multiple myeloma. Hematology 2023 Dec; 28(1): 2255800. doi: 10.1080\/1607 8454 .20 23. 2255800. Epub 2023 Sep 21. PMID: 37732626;","DOI":"10.1080\/16078454.2023.2255800"},{"key":"ref31","doi-asserted-by":"crossref","unstructured":"Xu Y Cao X , Zhou H, Xu H, Chen B, Bai H. Identifying potential prognosis markers in relapsed multiple myelo-ma via integrated bioinformatics analysis and biological experiments. Curr Res Transl Med 2025 Apr-Jun; 73(2): 103495. doi: 10.1016\/j.retram.2025.103495. Epub 2025 Jan 12. PMID: 39818172;","DOI":"10.1016\/j.retram.2025.103495"},{"key":"ref32","doi-asserted-by":"crossref","unstructured":"Wu L, Li H, Liu Y, Fan Z, Xu J, Li N, Qian X , Lin Z, Li X, Yan J. Research progress of 3D-bioprinted functional pancreas and in vitro tumor models. International Journal of Bioprinting 2024; 10(1): 1256. doi: 10.36922\/ ijb.1256;","DOI":"10.36922\/ijb.1256"},{"key":"ref33","doi-asserted-by":"crossref","unstructured":"You H, Yao W, Yan L, Zhai Y, Yan Z, Shang J, Yan S, Shi X , Jin S, Ge X , Shen H, Pan J, Wu D, Fu C. Poor progno-sis of newly diagnosed multiple myeloma patients with 1p32.3 deletion in single monoallelic deletion and\/or in main clone. Br J Hematol 2025 Sep; 207(3): 869-80. doi: 10.1111\/bjh.7001 5. Epub 2025 Aug 17. PMID: 40824203; PMCID: PMC12436220;","DOI":"10.1111\/bjh.70015"},{"key":"ref34","doi-asserted-by":"crossref","unstructured":"Wang F , Shen C. Impact of liquid liquid phase separationand immune-related gene signatures on multiple myelo-ma prognosis: focus on DDX21 and EZH2. Hematology 2025 Dec; 30(1): 2445403. doi: 10.1080\/16078454. 2024.2445403. Epub 2024 Dec 23. PMID: 39713879;","DOI":"10.1080\/16078454.2024.2445403"}],"container-title":["Journal of Medical Biochemistry"],"original-title":["Analiza korelacije serumske CCL3, TRACP-5b i sklerostina sa prognozom kod pacijenata sa multiplim mijelomom"],"language":"en","link":[{"URL":"https:\/\/scindeks-clanci.ceon.rs\/data\/pdf\/1452-8258\/2026\/1452-82582606286J.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T13:56:33Z","timestamp":1781618193000},"score":1,"resource":{"primary":{"URL":"https:\/\/scindeks.ceon.rs\/Article.aspx?artid=1452-82582606286J"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":36,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.5937\/jomb0-62533","relation":{},"ISSN":["1452-8258","1452-8266"],"issn-type":[{"value":"1452-8258","type":"print"},{"value":"1452-8266","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026]]}}}